StreetAlpha.app
Home › Stocks › AMRX

Amneal Pharmaceuticals, Inc. (AMRX)

Healthcare
$21.12
▼ −0.52%
LAST CLOSE · NOV 17

Amneal makes and sells generic, specialty and injectable medicines and distributes pharmaceuticals to government and retail buyers. It last closed at $21.12 on Nov 17, down 0.52% on the day. The average 12-month price target from 4 analysts is $24.25 (+14.8% from the last close), with a high of $27.00 and a low of $20.00. Analyst consensus is Strong Buy, based on the latest ratings from 4 firms (4 buy, 0 hold, 0 sell). In the past 30 days there were 1 dark pool print totaling $1.5M, the largest $1.5M.

AI Auto Pilots
Is AMRX in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$3.2B
+8.9% vs a year ago
Net income
$133.3M
+2159.3% vs a year ago
EPS (diluted)
$0.40
+3900.0% vs a year ago
Free cash flow
$88.2M
2.8% margin
Valuation
Market cap
$7.4B
348.4M shares
P/E
52.8
Price over 12 month EPS
Price to sales
2.3
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$157.4M
At Sep 30
Debt
$2.9B
At Sep 30
Shareholder equity
$531.3M
Shares outstanding
348.4M
At Oct 30
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $2.1B$2.1BFY2021FY2022: $2.2B$2.2BFY2022FY2023: $2.4B$2.4BFY2023FY2024: $2.8B$2.8BFY2024FY2025: $3.0B$3.0BFY2025

From AMRX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 9). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Strong Buy
Based on 4 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
4firms
4 Buy0 Hold0 Sell
Each firm's latest rating on AMRX in the past 90 days
Average 12-month target
$24.25
▲ 14.8% upside

Based on 4 analysts who set a price target on AMRX in the past 90 days. The average target is $24.25, with a high of $27.00 and a low of $20.00, compared with the last close of $21.12.

Low $20.00Avg $24.25High $27.00
Blue marker: last close $21.12
Highest target$27.00
Average target$24.25
Lowest target$20.00
Latest rating changes
Leerink PartnersTarget raised
Nov 5Buy$23 → $25
JP MorganTarget raised
Nov 4Buy$24 → $25
JP MorganTarget raised
Oct 22Buy$22 → $24
OppenheimerInitiated
Sep 23Buy$27
BarclaysTarget raised
Sep 17Buy$16 → $20
DateFirmActionRatingPrice target
Nov 5Leerink PartnersTarget raisedBuy$23 → $25
Nov 4JP MorganTarget raisedBuy$24 → $25
Oct 22JP MorganTarget raisedBuy$22 → $24
Sep 23OppenheimerInitiatedBuy$27
Sep 17BarclaysTarget raisedBuy$16 → $20
Loading…

Technical Analysis

AMRX · as of the Nov 17 close · updated after every close
Uptrend

The stock is 1% above its 20 day and 6% above its 50 day average. It is 23% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 56). The nearest support is the Pivot at $21.03, and the nearest resistance the swing high (Sep 21) at $21.18.

Short trendBullish
Long trendBullish
MomentumStrong
StretchNormal
VolatilityHigh, 3.5%/day
Key levels
$22.0752 week high+4.5%
$21.32Pivot R1+0.9%
$21.18Swing high (Sep 21)+0.3%
$21.12Last close
$21.03Pivot−0.4%
$20.8820 day average−1.1%
$20.84Pivot S1−1.3%
$19.8750 day average−5.9%
$19.02Swing low (Nov 4)−9.9%
$18.81100 day average−10.9%
$16.17200 day average−23.4%
$11.3952 week low−46.1%
Indicators
RSI (14)55.91Middle of its rangeNeutral
MACD0.41Above its signal lineBullish
Stochastic73.1Middle of its rangeNeutral
ADX (14)14.5No clear trend
Williams %R-31.0Oversold below −80, overbought above −20Neutral
CCI (20)20.8Oversold below −100, overbought above 100Neutral
Rate of change+4.5%Change over 10 sessionsBullish
ATR (14)$0.75Typical daily range, 3.5% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for AMRX

What happened before

See how AMRX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow AMRX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How AMRX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2009.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in AMRX in the last 90 days.

Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
1
Notional
$1.5M
Largest print
$1.5M
Loading…

AMRX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲190 buying vs 131 selling
  • ●Held by funds +0.2 pts
  • ▲Funds holding +27
  • ▲Superinvestors: 2 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding336309+8.7%
In funds' top 1057−28.6%
Held by funds48.6%48.3%+0.2 pts
New / increased61 / 12943 / 137+5.6%
Reduced / sold out98 / 3383 / 52−3.0%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See AMRX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether AMRX is in one of them and how their past AMRX trades turned out.

AMRX in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered AMRX in an article yet. Here's the latest on the wider market.

AMRX Congress Trades

All congress trades →
Trades, 12 months
0
Buys
0
Sells
0
People
0
Last filed Jun 18
Who traded AMRX · since 2019
Latest 2 filings
$1K – $15KTraded May 29, 2019Filed Jun 18, 2019
$1K – $15KTraded May 24, 2019Filed Jun 15, 2019
PersonTypeAmountTradedFiledDelay
Gilbert CisnerosD · CASell$1K – $15KMay 29, 2019Jun 18, 201920 d
Josh GottheimerD · NJSell$1K – $15KMay 24, 2019Jun 15, 201922 d

Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.

About Amneal Pharmaceuticals

Amneal develops, makes, markets and distributes medicines through three business areas. Its Affordable Medicines segment offers retail generic drugs, injectable products and biosimilars, while its Specialty segment sells branded drugs mainly for central nervous system and endocrine disorders. Its AvKARE unit distributes pharmaceuticals and other products to the U.S. federal government, retail customers and institutional buyers. The company operates mainly in the United States, India and Ireland.